First isolation of kpc in Chile: From Italy to a public hospital in Santiago;Primer caso de detección de blaKPC en Chile: Desde Italia a un hospital público de Santiago

Revista Chilena de Infectologia

Volumn 29, Issue 2, 2012, Pages 224-228

  Cifuentes, Marcela ^a   García, Patricia ^b   Martín, Paola San ^a   Silva, Francisco ^c   Zúñiga, Jennifer ^a   Reyes, Sergio ^a   Rojas, Rodrigo ^a   Ponce, Rodrigo ^a   Quintanilla, Raúl ^a   Delpiano, Luis ^a   Wolff, Marcelo ^a  

^a HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Antimicrobial resistance; Carbapenemase; KPC

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; CASE REPORT; CHILE; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; ITALY; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NONHODGKIN LYMPHOMA;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CHILE; HUMANS; ITALY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LYMPHOMA, NON-HODGKIN; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 84861942026     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182012000200018     Document Type: Article

References (10)

1. Jacoby G A, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352: 380-91.
2. Patel G, Huprikar S, Factor S H, Jenkins S G, Calfee D P, et al. Outcomes of carbapenemresistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. M100-S20. Vol 30 No 1. (2010).
4. Centers for Disease Control and Human Services. Laboratory protocol for detection of carbapenem-resistant or carbapenemaseproducing Klebsiella spp and E. coli from rectal swabs. http://www.cdc.gov/HAI/pdfs/ labSettings/Klebsiella_or_Ecoli.pdf
5. Wozniak A, Undabarrena A, Villagra N, Gallardo N, Keller N, Moraga M, Román J C, Mora G, García P. Rol de las porinas y su caracterización en la resistencia a carbapenémicos en aislados clínicos de Enterobacteriaceae. XXVIII Congreso Chileno de Infectología, Coquimbo, 30 de noviembre, 1 y 2 de diciembre de 2011. Rev Chilena Infectol 2011; 28 (Supl 2): S51. Resumen CO-3.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty Second Informational Supplement. M100-S22. Vol 32 No 3 (2012).
7. Gupta N, Limbago B, Patel J, Kallen A. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011; 53 (1): 60-7.
8. Silva F, Cifuentes M, Pinto M E y Grupo Colaborativo de Resistencia. Resultados de la vigilancia de susceptibilidad antimicrobiana en Chile: Consolidando una red. Rev Chilena Infectol 2010; 28 (1): 19-27.
9. Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, et al. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard defi nitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
10. Centers for Disease Control and Prevention. Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities, http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5810a4.htm